EP1968645A4 - Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations - Google Patents

Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations

Info

Publication number
EP1968645A4
EP1968645A4 EP06846650A EP06846650A EP1968645A4 EP 1968645 A4 EP1968645 A4 EP 1968645A4 EP 06846650 A EP06846650 A EP 06846650A EP 06846650 A EP06846650 A EP 06846650A EP 1968645 A4 EP1968645 A4 EP 1968645A4
Authority
EP
European Patent Office
Prior art keywords
mimetibodies
compositions
methods
related disorders
treating obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06846650A
Other languages
German (de)
English (en)
Other versions
EP1968645A2 (fr
Inventor
Karyn T O'neil
Kristen Picha
Vedrana Stojanovic-Susulic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of EP1968645A2 publication Critical patent/EP1968645A2/fr
Publication of EP1968645A4 publication Critical patent/EP1968645A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP06846650A 2005-12-22 2006-12-18 Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations Withdrawn EP1968645A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75282605P 2005-12-22 2005-12-22
PCT/US2006/062223 WO2007076319A2 (fr) 2005-12-22 2006-12-18 Corps mimetiques humains glp-1 et compositions pour traiter l’obesite et les troubles associes, procedes et utilisations

Publications (2)

Publication Number Publication Date
EP1968645A2 EP1968645A2 (fr) 2008-09-17
EP1968645A4 true EP1968645A4 (fr) 2009-11-04

Family

ID=38218787

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06846650A Withdrawn EP1968645A4 (fr) 2005-12-22 2006-12-18 Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations

Country Status (4)

Country Link
EP (1) EP1968645A4 (fr)
JP (1) JP2009526750A (fr)
CA (1) CA2634784A1 (fr)
WO (1) WO2007076319A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064623A1 (es) * 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
EP2214700A4 (fr) * 2007-11-02 2012-08-22 Janssen Biotech Inc Produits d'assemblage semi-synthétiques obtenus par fusion de peptide glp-1/fc, procédés et utilisations
JP5889533B2 (ja) * 2008-01-31 2016-03-22 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変された抗体定常ドメイン分子
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020201280A1 (fr) 2019-04-01 2020-10-08 Novo Nordisk A/S Anticorps dirigés contre le liraglutide et leur utilisation
CA3181300A1 (fr) 2020-06-03 2021-12-09 Christoffer CLEMMENSEN Conjugues d'antagoniste de nmdar agoniste du glp1r

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005231359A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADELHORST K ET AL: "STRUCTURE-ACTIVITY STUDIES OF GLUCAGON-LIKE PEPTIDE-1", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 269, no. 9, 4 March 1994 (1994-03-04), pages 6275 - 6278, XP002045291, ISSN: 0021-9258 *
NASLUND E ET AL: "Glucagon-like peptide-1 in the pathogenesis of obesity", DRUG NEWS AND PERSPECTIVES 1998 ES, vol. 11, no. 2, 1998, pages 92 - 97, XP001539560, ISSN: 0214-0934 *
PICHA KRISTEN M ET AL: "Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis", DIABETES, vol. 57, no. 7, July 2008 (2008-07-01), pages 1926 - 1934, XP002547063, ISSN: 0012-1797 *

Also Published As

Publication number Publication date
JP2009526750A (ja) 2009-07-23
WO2007076319A3 (fr) 2008-10-30
CA2634784A1 (fr) 2007-07-05
EP1968645A2 (fr) 2008-09-17
WO2007076319A2 (fr) 2007-07-05

Similar Documents

Publication Publication Date Title
IL178432A0 (en) Human glp-1 mimetibodies, compositions, methods and uses
ZA200901132B (en) Human GLP-1 mimetibodies, compositions, methods and uses
GB0525041D0 (en) Methods, assays and compositions for treating retinol-related diseases
EP1959929A4 (fr) Compositions et procedes pour le traitement de conditions dermatologiques
IL186963A0 (en) Methods and compositions for treating pain
IL177717A0 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
HUE039108T2 (hu) Készítmények és eljárások szembetegségek kezelésére
IL190913B (en) Preparations for the treatment of sweating disorders
EP1890712A4 (fr) Compositions et methodes de traitement de la douleur
PL1863899T3 (pl) Kompozycje do leczenia skóry
IL179766A0 (en) Compositions and methods using same for treating neurodegenerative disorders
HK1214158A1 (zh) 治療澱粉樣變性的製劑和方法
IL185861A0 (en) Method and composition for treating mucosal disorders
ZA200804500B (en) Methods and compositions for the treatment of gastro-intestinal disorders
EP1968645A4 (fr) Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations
EP1898921A4 (fr) Compositions et methodes servant a traiter les troubles du sommeil
EP1942909A4 (fr) Méthodes de traitement de troubles respiratoires
ZA200708408B (en) Method and composition for treating mucosal disorders
GB0715870D0 (en) Composition and methods for reducing body fat content, treating obesity and related disorders
IL186307A0 (en) Human glp-1 mimetibodies, compositions, methods and uses
GB0419497D0 (en) Method,composition and device for treating starch related diseases
ZA200608999B (en) Human GLP-1 mimetibodies, compositions, methods and uses
GB0505203D0 (en) Skin composition treatment
PL2374472T3 (pl) Kompozycje i sposoby leczenia zaburzeń okulistycznych
GB2433935B (en) Compounds for treating diabetes and related disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080718

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20081030

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 5/00 20060101ALI20081118BHEP

Ipc: A61K 38/04 20060101ALI20081118BHEP

Ipc: A61K 38/00 20060101AFI20081118BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1124539

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CENTOCOR ORTHO BIOTECH INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20091005

17Q First examination report despatched

Effective date: 20100204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100615

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1124539

Country of ref document: HK